Jefferson Luiz da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jefferson Luiz da Silva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Soares Ferreira Junior
Department of Genetics, Microbiology and Immunology, Institute of Biosciences, Sao Paulo State University, Botucatu, Sao Paulo, Brazil, Brazil
3 shared publications - Gislane Lelis Vilela de Oliveira
Department of Genetics, Microbiology and Immunology, Institute of Biosciences (IBB), Sao Paulo State University (UNESP), Botucatu, Brazil, Brazil
3 shared publications - Nelson J. Chao
Duke University Medical Center, Durham, North Carolina, United States
3 shared publications - Bianca Fernanda Rodrigues da Silva
Department of Genetics, Microbiology and Immunology, Institute of Biosciences (IBB), Sao Paulo State University (UNESP), Botucatu 18618-970, Sao Paulo, Brazil
2 shared publications - João Victor Piccolo Feliciano
Faculdade Regional de Medicina de São José do Rio Preto – São José do Rio Preto (SP), Brazil
2 shared publications - Mariana Trovao da Silva
Department of Genetics, Microbiology and Immunology, Institute of Biosciences, Sao Paulo State University, Botucatu 18618-970, SP, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 308
Oral Microbiota and Clinical Outcomes in Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review
In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), emerging evidence suggests that the oral microbiota may serve as a predictive biomarker. We conducted a systematic review to provide a critical overview of oral microbiota research in the allo-HSCT setting. We searched PubMed, Embase, and Web of Science from inception to December 2025 to identify studies assessing the oral microbiota in allo-HSCT settings. We included all articles reporting detailed data on the oral microbiota in this context and conducted a qualitative synthesis. Risk of bias was assessed using the JBI critical appraisal tools. From 8160 initially identified records, 35 studies evaluating the oral microbiota in 1964 allo-HSCT patients were included. Of these, 27 studies (77%) assessed temporal oral microbiota dynamics and reported dysbiosis in the early post-transplantation period, followed by gradual recovery. Additionally, 27 studies (77%) evaluated the prognostic value of the oral microbiota, identifying associations with key clinical outcomes such as oral mucositis, overall survival, and graft-versus-host disease. Finally, substantial methodological heterogeneity was observed across studies, including differences in sampling techniques, sampling timepoints, and analytical strategies. This systematic review highlights the prognostic and therapeutic potential of the oral microbiota in allo-HSCT and underscores the need for standardized methodologies.
- 28 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 308
Open AccessOral Microbiota and Clinical Outcomes in Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review
In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), emerging evidence suggests that the oral microbiota may serve as a predictive biomarker. We conducted a systematic review to provide a critical overview of oral microbiota research in the allo-HSCT setting. We searched PubMed, Embase, and Web of Science from inception to December 2025 to identify studies assessing the oral microbiota in allo-HSCT settings. We included all articles reporting detailed data on the oral microbiota in this context and conducted a qualitative synthesis. Risk of bias was assessed using the JBI critical appraisal tools. From 8160 initially identified records, 35 studies evaluating the oral microbiota in 1964 allo-HSCT patients were included. Of these, 27 studies (77%) assessed temporal oral microbiota dynamics and reported dysbiosis in the early post-transplantation period, followed by gradual recovery. Additionally, 27 studies (77%) evaluated the prognostic value of the oral microbiota, identifying associations with key clinical outcomes such as oral mucositis, overall survival, and graft-versus-host disease. Finally, substantial methodological heterogeneity was observed across studies, including differences in sampling techniques, sampling timepoints, and analytical strategies. This systematic review highlights the prognostic and therapeutic potential of the oral microbiota in allo-HSCT and underscores the need for standardized methodologies.
- Open Access
- 28 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 6874
Unraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions
Intestinal dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Distinct microbiota patterns represent potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity has created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: (1) decreased intestinal microbiota diversity, (2) reduced abundance of short-chain fatty acid-producing bacteria, and (3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, Graft-versus-host disease, transplant-related mortality, and infection-related complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite significant advances in microbiota research, biological, methodological, and logistical challenges continue to hinder its clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.
- 28 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 6874
Open AccessUnraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions
Intestinal dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Distinct microbiota patterns represent potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity has created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: (1) decreased intestinal microbiota diversity, (2) reduced abundance of short-chain fatty acid-producing bacteria, and (3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, Graft-versus-host disease, transplant-related mortality, and infection-related complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite significant advances in microbiota research, biological, methodological, and logistical challenges continue to hinder its clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.
- Open Access
- 28 August 2025
- Published by MDPI AG in Preprints.org
Unraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions
Intestinal microbiota dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with distinct microbiota patterns serving as potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity have created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: 1) decreased intestinal diversity, 2) reduced abundance of short-chain fatty acid-producing bacteria, and 3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, graft-versus-host disease, transplant-related mortality, and infectious complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite advances in microbiota research, biological, methodological, and logistical challenges continue to impede clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.
- 28 August 2025
- Published by MDPI AG in Preprints.org
Open AccessUnraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions
Intestinal microbiota dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with distinct microbiota patterns serving as potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity have created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: 1) decreased intestinal diversity, 2) reduced abundance of short-chain fatty acid-producing bacteria, and 3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, graft-versus-host disease, transplant-related mortality, and infectious complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite advances in microbiota research, biological, methodological, and logistical challenges continue to impede clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.